BBIO Q1 2021 Earnings — BridgeBio Pharma, Inc. Revenue & Financial Results | Market Cap Arena

BBIOBridgeBio Pharma, Inc.

$14B

Q1 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$462,000

Gross Profit

$462,000100.0% margin

Operating Income

-$168M-36256.3% margin

Net Income

-$163M-35298.5% margin

EPS (Diluted)

$-1.18

QoQ Revenue Growth

+278.7%

Cash Flow

Operating Cash Flow

-$151M

Free Cash Flow

-$153M

Stock-Based Comp.

$34M

Balance Sheet

Total Assets

$1.1B

Total Liabilities

$1.5B

Stockholders' Equity

-$395M

Cash & Equivalents

$471M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$462,000	$0	—
Gross Profit	$462,000	$0	—
Operating Income	-$168M	-$102M	-63.4%
Net Income	-$163M	-$92M	-77.5%